Skip to main content
OREGON STATE UNIVERSITY
Open search box
Linus Pauling Institute
Toggle menu
Go to search page
Search Field
Exit Search
About the LPI
Faculty and Staff
Our Research
Micronutrient Information
Publications
Micronutrients for Health
Contact Information
Donate
About the LPI
Faculty and Staff
Our Research
Micronutrient Information
Publications
Contact Information
Donate
Biblio
Found 17 results
Author
[
Keyword
]
Title
Type
Year
Filters:
Author
is
Bradley, Ryan
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Adult
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Biological Products
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Biomarkers
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Clinical Trials, Phase II as Topic
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Crohn Disease
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Flavonoids
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Gastrointestinal Microbiome
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Humans
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Inflammation
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Microbiota
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
Prebiotics
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Propiophenones
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Randomized Controlled Trials as Topic
Langley BO
,
Ryan JJoan
,
Phipps J
,
Buttolph L
,
Bray B
,
Aslan JE
,
Metz TO
,
Stevens JF
,
Bradley R
. 2022.
Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
.
Trials. 23(1):885.
RNA, Ribosomal, 16S
Jamieson PE
,
Smart EB
,
Bouranis JA
,
Choi J
,
Danczak RE
,
Wong CP
,
Paraiso IL
,
Maier CS
,
Ho E
,
Sharpton TJ
et al.
. 2024.
Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults.
.
Gut Microbes. 16(1):2315633.
Donate Today!
Get Updates from the Institute